Jump Financial’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Jump Financial’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-86,865	Closed	-$365K	–	2291
2023 Q1	$365K	Sell	86,865 -4,828	-5%	-$25.1K	0.01%	1031
2022 Q4	$551K	Buy	91,693 +58,204	+174%	+$318K	0.03%	727
2022 Q3	$195K	Sell	33,489 -75,034	-69%	-$468K	0.01%	1353
2022 Q2	$648K	Buy	+108,523	New	+$556K	0.03%	736
2021 Q1	–	Sell	-38,800	Closed	-$125K	–	1447
2020 Q4	$125K	Buy	+38,800	New	+$129K	0.02%	844

Other funds holding CTIC

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Jump Financial's CTIC Position: Q2 2023 in Review

Jump Financial sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 86,865 shares — an estimated $365K sold.

Jump Financial first reported a position in CTIC in Q4 2020 and held it in 5 quarters. The position peaked at $648K in Q2 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Jump Financial reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Jump Financial sold 86,865 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $365K.
Jump Financial first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2020 and held it in 5 quarters.
Jump Financial's CTI BioPharma Corp. (DE) Common Stock position peaked at $648K in Q2 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Jump Financial's 13F filing for Q2 2023, filed 7 Aug 2023.